Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 16/20 | 0.45 |
| ▸ | CDC25B | P30305 | 14/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 13/20 | 0.35 |
| ▸ | CDC25C | P30307 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198983 | 1.00 | MAPT (0.48) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL592859 | 1.00 | MAPT (0.48) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL2794781 | 0.82 | MAPT (0.46) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL6929222 | 0.79 | MAPT (0.42) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL9717843 | 0.79 | MAPT (0.38) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL4959979 | 0.79 | MAPT (0.43) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL14306447 | 0.77 | DUSP3 (0.42) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL9541659 | 0.77 | DUSP3 (0.42) | MAPTLMNAL3MBTL1DUSP3CDC25B | |
| SCHEMBL7985437 | 0.76 | MAPT (0.40) | MAPTLMNAL3MBTL1KDM4E | |
| SCHEMBL6927981 | 0.76 | MAPT (0.44) | MAPTLMNAL3MBTL1DUSP3CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138691-B2 | Method for the synthesis of mesoporous platinum nanoparticles in an aqueous environment | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-11-12 | — | — | US | claimed |
| EP-3956086-A1 | METHOD FOR THE SYNTHESIS OF MESOPOROUS PLATINUM NANOPARTICLES IN AN AQUEOUS ENVIRONMENT | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-02-23 | — | — | EP | claimed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| US-20240026416-A1 | System and Method for Liquid Culture of Anaerobic or Microaerophilic Microorganisms | NEOGEN FOOD SAFETY US HOLDCO CORP (US) | 2024-01-25 | — | — | US | disclosed |
| US-11685944-B2 | System and method for liquid culture of anaerobic or microaerophilic microorganisms | NEOGEN FOOD SAFETY US HOLDCO CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220228190-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3956086-A1 | METHOD FOR THE SYNTHESIS OF MESOPOROUS PLATINUM NANOPARTICLES IN AN AQUEOUS ENVIRONMENT | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-02-23 | — | — | EP | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-7642064-B2 | Binding enzyme-labeled conjugate (antibodies, haptens with phospatases, galactosidases, beta-glucosidases, esterases, and beta-lactamases) to epitope/sequence in presence of redox-inactive reductive species and soluble gold/silver ion; solid phase synthesis; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | MAPT 1771/4885LMNA 2887/4885L3MBTL1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.